Screener
Immunovant, Inc. IMVT Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | Years Ended March 31, 2026 | Years Ended March 31, 2025 | Years Ended March 31, 2024 |
|---|---|---|---|
| Research and development | $456,660 | $360,917 | $212,928 |
| Acquired in-process research and development | — | — | 12,500 |
| General and administrative | 76,242 | 77,235 | 57,281 |
| Total operating expenses | 532,902 | 438,152 | 282,709 |
| Interest income, net | (25,330) | (24,732) | (24,948) |
| Other (income) expense, net | (2,181) | (471) | 1,008 |
| Loss before provision for income taxes | (505,391) | (412,949) | (258,769) |
| Provision for income taxes | 215 | 891 | 567 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s total operating expenses?
- Immunovant, Inc. (IMVT) reported total operating expenses of $159.55M in Q1 2026.
- How has Immunovant, Inc.'s total operating expenses changed year-over-year?
- Immunovant, Inc.'s total operating expenses increased by 40.2% year-over-year, from $113.83M to $159.55M.
- What is the long-term trend for Immunovant, Inc.'s total operating expenses?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s total operating expenses has grown at a 35.9% compound annual growth rate (CAGR), from $156.03M to $532.9M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Immunovant, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude